Literature DB >> 3929312

Buprenorphine effects on cigarette smoking.

N K Mello, S E Lukas, J H Mendelson.   

Abstract

Cigarette smoking increased during administration of buprenorphine, an opioid mixed agonist-antagonist, in comparison to drug-free baseline in seven heroin addicts maintained on buprenorphine for 24 days (P less than 0.01-0.001). Ascending buprenorphine doses (0.5 - 8.0 mg/day) were associated with significant increases in cigarette smoking at doses of 2.0 mg/day sc and above. Cigarette smoking during 10 days of buprenorphine maintenance at 8 mg/day was significantly higher than during the buprenorphine induction phase (P less than 0.01). Six subjects given placebo buprenorphine over 14 days showed no change in cigarette smoking. The placebo group self-administered heroin for 10 days, and cigarette smoking increased significantly during heroin use (P less than 0.001). The rate of cigarette smoking defined by intercigarette intervals was highest during the 10 days of high-dose buprenorphine maintenance or placebo plus heroin self-administration. Both groups requested significantly more cigarettes at intervals of 0-10, 11-20, and 21-30 min than during the drug-free baseline. These data confirmed previous findings that opioid agonist administration is associated with increased cigarette smoking and suggest that buprenorphine has primarily agonist effects on cigarette smoking.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3929312     DOI: 10.1007/bf00427902

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  35 in total

1.  The effects of d-amphetamine, meprobamate, and lobeline on the cigarette smoking behavior of normal human subjects.

Authors:  C R Schuster; B R Lucchesi; G S Emley
Journal:  NIDA Res Monogr       Date:  1979-01

2.  Facilitation of human tobacco self-administration by ethanol: a behavioral analysis.

Authors:  R R Griffiths; G E Bigelow; I Liebson
Journal:  J Exp Anal Behav       Date:  1976-05       Impact factor: 2.468

3.  Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction.

Authors:  D R Jasinski; J S Pevnick; J D Griffith
Journal:  Arch Gen Psychiatry       Date:  1978-04

4.  Neuroendocrine reactivity to nicotine in smokers.

Authors:  O F Pomerleau; J B Fertig; L E Seyler; J Jaffe
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

5.  The effect of naloxone on pulsatile gonadotrophin release in normal subjects.

Authors:  P J Moult; A Grossman; J M Evans; L H Rees; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1981-03       Impact factor: 3.478

6.  Plasma testosterone levels in heroin addiction and during methadone maintenance.

Authors:  J H Mendelson; J E Mendelson; V D Patch
Journal:  J Pharmacol Exp Ther       Date:  1975-01       Impact factor: 4.030

7.  Plasma testosterone levels during chronic heroin use and protracted astinence. A study of Hong Kong addicts.

Authors:  J H Mendelson; N K Mello
Journal:  Clin Pharmacol Ther       Date:  1975-05       Impact factor: 6.875

8.  Cigarette smoking and subjective response: effects of d-amphetamine.

Authors:  J E Henningfield; R R Griffiths
Journal:  Clin Pharmacol Ther       Date:  1981-10       Impact factor: 6.875

9.  Endorphin levels in opioid-dependent human subjects: a longitudinal study.

Authors:  C P O'Brien; L Terenius; A Wahlström; A T McLellan; W Krivoy
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

10.  Ethanol inhibits the naloxone-induced release of luteinizing hormone-releasing hormone from the hypothalamus of the male rat.

Authors:  T J Cicero; K S Newman; M Gerrity; P F Schmoeker; R D Bell
Journal:  Life Sci       Date:  1982-10-11       Impact factor: 5.037

View more
  29 in total

1.  Evaluating Nicotine Craving, Withdrawal, and Substance Use as Mediators of Smoking Cessation in Cocaine- and Methamphetamine-Dependent Patients.

Authors:  Joshua C Magee; Daniel F Lewis; Theresa Winhusen
Journal:  Nicotine Tob Res       Date:  2015-06-05       Impact factor: 4.244

Review 2.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

Review 3.  Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review.

Authors:  Sarah C Akerman; Mary F Brunette; Alan I Green; Daisy J Goodman; Heather B Blunt; Sarah H Heil
Journal:  J Subst Abuse Treat       Date:  2014-12-22

Review 4.  Are Pharmacotherapies Ineffective in Opioid-Dependent Smokers? Reflections on the Scientific Literature and Future Directions.

Authors:  Mollie E Miller; Stacey C Sigmon
Journal:  Nicotine Tob Res       Date:  2015-08       Impact factor: 4.244

5.  Smoking and opioid detoxification: behavioral changes and response to treatment.

Authors:  Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; David A Gorelick
Journal:  Nicotine Tob Res       Date:  2013-04-09       Impact factor: 4.244

6.  Spontaneous reductions in smoking during double-blind buprenorphine detoxification.

Authors:  Mollie E Patrick; Kelly E Dunn; Gary J Badger; Sarah H Heil; Stephen T Higgins; Stacey C Sigmon
Journal:  Addict Behav       Date:  2014-05-05       Impact factor: 3.913

7.  Investigating tobacco withdrawal in response to reduced nicotine cigarettes among smokers with opioid use disorder and other vulnerabilities.

Authors:  Joanna M Streck; Stacey C Sigmon; Jeffrey Priest; Cecilia L Bergeria; Danielle R Davis; John R Hughes; Andrea C Villanti; Jennifer W Tidey; Sarah H Heil; Diann E Gaalema; Maxine L Stitzer; Stephen T Higgins
Journal:  Exp Clin Psychopharmacol       Date:  2020-02-06       Impact factor: 3.157

8.  Contingency management for behavior change: applications to promote brief smoking cessation among opioid-maintained patients.

Authors:  Kelly E Dunn; Kathryn A Saulsgiver; Stacey C Sigmon
Journal:  Exp Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.157

9.  Naloxone does not affect cigarette smoking.

Authors:  R Nemeth-Coslett; R R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 10.  Hormones, nicotine, and cocaine: clinical studies.

Authors:  Nancy K Mello
Journal:  Horm Behav       Date:  2009-10-14       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.